Acute ischemic stroke remains a predominant cause of acquired physical disability and late-onset seizures among older adults worldwide. Consequently, hospital discharge represents a vulnerable transitional period where clinicians frequently confront difficult therapeutic choices. A comprehensive evaluation of outpatient epilepsy-specific medication initiation after acute ischemic stroke highlights evolving practice patterns and therapeutic variations. By examining real-world observational data, clinicians can better appreciate how post-discharge anti-seizure strategies impact elderly populations. Understanding these treatment trajectories provides valuable guidance for secondary neurovascular and neurological management.

Epidemiological Significance of Post-Stroke Seizures

Cerebrovascular events account for nearly half of all newly diagnosed epilepsy cases in patients aged 65 years and older. Post-stroke seizures typically divide into acute symptomatic seizures, occurring within seven days of ischemia, and unprovoked late seizures. Furthermore, late seizures reflect permanent structural changes, gliosis, and altered cortical excitability. These pathological alterations markedly elevate the risk of recurrent unprovoked seizures, fulfilling the clinical diagnostic criteria for post-stroke epilepsy. Notably, recurrent seizure episodes severely diminish quality of life and accelerate cognitive decline. Patients experiencing post-stroke seizures also face an elevated hazard of all-cause mortality and prolonged physical rehabilitation. Therefore, prompt clinical recognition of epileptogenesis is vital for optimizing neurological recovery. International guidelines discourage routine primary anti-seizure prophylaxis for all ischemic stroke survivors. However, clinicians regularly face complex clinical scenarios where cortical damage or transient convulsive episodes necessitate definitive outpatient pharmacotherapy.

Trends in Epilepsy-Specific Medication Initiation Over Time

Recent nationwide evidence indicates that epilepsy-specific medication initiation after hospital discharge has steadily increased over the past decade. An analysis of over 128,000 Medicare beneficiaries hospitalized for acute ischemic stroke between 2013 and 2021 revealed meaningful temporal shifts. Overall, 1.9% of community-dwelling survivors initiated anti-seizure pharmacotherapy within 90 days of discharge. Moreover, the cumulative 90-day incidence of medication initiation climbed from 1.2% in 2013 to 1.7% in 2021. This upward trajectory suggests growing clinical awareness regarding the morbidity associated with post-stroke seizures. Additionally, improved diagnostic tools, such as continuous electroencephalography during initial hospitalization, likely identify more subclinical epileptiform discharges. Consequently, modern hospitalists and neurologists appear more proactive in prescribing outpatient anti-seizure regimens. As post-stroke survivorship expands globally, this progressive increase highlights the growing importance of structured outpatient neurological follow-up.

Racial and Geographic Disparities in Prescribing Patterns

The observational data also uncover noticeable racial, ethnic, and geographic variations in post-stroke management. Specifically, Black and African American beneficiaries had a 90-day cumulative initiation rate of 1.8%, while Hispanic beneficiaries exhibited an initiation rate of 1.9%. In contrast, non-Hispanic White stroke survivors demonstrated a lower cumulative initiation rate of 1.2%. Furthermore, geographic variations across the United States revealed substantial differences, ranging from 1.0% in the West North Central division to 1.5% in the East South Central division. These epidemiological variations point toward underlying disparities in baseline vascular risk factors, stroke severity, and access to specialized neurology consultations. In addition, unequal availability of post-discharge care coordinators and diagnostic monitoring may shape distinct clinical management pathways. Recognizing these sociodemographic variations encourages healthcare providers to evaluate regional practice habits and ensure equitable care delivery across all patient populations.

Pharmacological Dominance and Clinical Role of Levetiracetam

Among older stroke survivors who initiated anti-seizure therapy, levetiracetam emerged as the overwhelmingly dominant agent, accounting for 81% of all outpatient prescriptions. Clinicians consistently favor levetiracetam because of its favorable pharmacokinetic profile and absence of substantial cytochrome P450 hepatic enzyme induction. This characteristic represents a critical advantage for older stroke survivors, who routinely require complex secondary prevention regimens including statins, antiplatelets, and anticoagulants. Older anti-seizure medications, such as phenytoin and carbamazepine, induce hepatic enzymes and frequently disrupt serum concentrations of cardiovascular drugs. In addition, levetiracetam offers high oral bioavailability and straightforward dosing titration. However, clinicians must remain vigilant regarding potential adverse effects. Behavioral disturbances, irritability, somnolence, and an elevated risk of accidental falls require close monitoring, especially in frail geriatric cohorts. Alternative modern agents, including lamotrigine and lacosamide, provide valuable secondary options when behavioral toxicity limits levetiracetam tolerability.

Age-Related Reductions in Outpatient Prescribing

Interestingly, data demonstrate that epilepsy-specific medication initiation is highest among patients aged 65 to 70 years, reaching 1.6%, but progressively declines in older cohorts. Clinicians often display greater therapeutic reluctance when treating the oldest-old, such as nonagenarians and centenarians. This conservative approach typically stems from concerns regarding polypharmacy, altered drug clearance, and heightened susceptibility to adverse drug reactions. Sedation and ataxia caused by anti-seizure medications can exacerbate underlying gait instability and precipitate catastrophic hip fractures. Furthermore, severe post-stroke cognitive impairment or dementia in very elderly patients may lead clinicians to adopt conservative management goals. Nonetheless, withholding necessary therapy can leave patients vulnerable to severe status epilepticus. Therefore, treating physicians must strike a delicate balance between seizure recurrence risk and medication-related adverse events. Comprehensive geriatric assessments and individualized risk-benefit analyses remain essential when deciding whether to initiate therapy.

Clinical Implications for Stroke Care in India and Globally

These findings offer valuable guidance for physicians managing stroke survivors across diverse clinical settings, including high-volume neurovascular centers in India. Stroke incidence in low- and middle-income countries continues to surge, shifting substantial long-term morbidity burdens to outpatient healthcare networks. Indian clinicians routinely encounter older stroke survivors presenting with late focal motor seizures or subtle non-convulsive episodes. In these settings, selecting second-generation agents with minimal drug-drug interactions is critical, given high rates of comorbid diabetes, hypertension, and ischemic heart disease. Furthermore, physicians should avoid reflexive, prolonged primary prophylaxis without documented seizure activity, as unwarranted anti-seizure therapy adds unnecessary financial burden and toxicity. Clinicians must educate family caregivers on recognizing early post-stroke seizure manifestations. Establishing structured post-discharge surveillance ensures timely pharmacotherapy initiation while preventing unwarranted polypharmacy, ultimately improving functional outcomes and survival among elderly stroke survivors.

Frequently Asked Questions

Why is levetiracetam preferred for post-stroke seizure management?

Clinicians prefer levetiracetam primarily because of its favorable pharmacokinetic profile and minimal hepatic cytochrome P450 interactions. This agent does not significantly interfere with secondary stroke medications like anticoagulants or antiplatelets. Furthermore, its parenteral and oral formulations offer predictable bioavailability, which greatly simplifies dosing in older patients with complex vascular disease.

When should clinicians initiate anti-seizure therapy after ischemic stroke?

Routine primary prophylaxis is generally discouraged following acute ischemic stroke. In contrast, clinicians should initiate anti-seizure medications when patients experience early unprovoked seizures with high recurrence risk or late unprovoked seizures defining post-stroke epilepsy. Clinicians must carefully weigh recurrence dangers against potential adverse drug reactions, sedation, and fall risks in elderly survivors.

What explains racial disparities in post-stroke seizure treatment?

Racial differences in post-stroke prescription patterns often reflect complex socio-demographic factors, baseline vascular comorbidity burdens, and stroke severity differences. Furthermore, structural disparities in outpatient access, diagnostic monitoring availability, and follow-up protocols can influence prescribing decisions. Understanding these variables ensures that clinicians deliver equitable, individualized post-stroke care across diverse patient cohorts.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Healthcare professionals must exercise independent clinical judgment. The dosages, indications, and clinical management strategies discussed may differ across healthcare jurisdictions. Refer to the latest local and national guidelines for clinical practice.

References

Donahue MA et al. Differences in patterns of outpatient epilepsy-specific medication initiation after acute ischemic stroke in the Medicare population. Epilepsia. 2025 Aug. doi: 10.1111/epi.18396. PMID: 40184019.

Holtkamp M, Beghi E, Benninger F, et al. European Stroke Organisation guidelines for the management of post-stroke seizures and epilepsy. European Stroke Journal. 2017;2(2):103-115.

Tanaka T, Ihara M. Post-stroke epilepsy: Challenges and perspectives. Neurochemistry International. 2017;107:219-228.

Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475-482.